|
1
|
Palmerini E, Picci P, Reichardt P and
Downey G: Malignancy in giant cell tumor of bone: A review of the
literature. Technol Cancer Res Treat.
18(1533033819840000)2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Geramizadeh B and Kazemi K:
Osteoclastoma-like giant cell tumor of the liver, an extremely rare
tumor. Hepatitis Monthly. 17(e56097)2017.
|
|
3
|
Angellotti G, Tomasicchio G, Montanaro AE,
Telgrafo M, Mastropasqua MG and Punzo C: Osteoclast-like stromal
giant cells in invasive ductal breast cancer: A case series. Int J
Surg Case Rep. 97(107421)2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Wang YJ, Huang CP, Hong ZJ, Liao GS and Yu
JC: Invasive breast carcinoma with osteoclast-like stromal giant
cells: A case report. World J Clin Cases. 11:1521–1527.
2023.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Niwa A, Tomita H, Watanabe N, Kiriyama S,
Hara A and Tanaka T: Case report: A case of gallbladder
carcinosarcoma with osteoclast-like multinucleated giant cells that
was associated with RANK-RANKL signaling. Pathol Oncol Res.
28(1610134)2022.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Zhao N, Mei Y, Yi H, Wang H, Wang Y, Yao Y
and Li C: Case report: Pathological and genetic features of
pancreatic undifferentiated carcinoma with osteoclast-like giant
cells. Pathol Oncol Res. 29(1610983)2023.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Baydar D, Amin MB and Epstein JI:
Osteoclast-rich undifferentiated carcinomas of the urinary tract.
Mod Pathol. 19:161–171. 2006.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Wu PJ, Su CK, Li JR, Yang CR and Chen CL:
Osteoclast-like giant cell carcinoma of the urinary bladder. J Chin
Med Assoc. 72:495–497. 2009.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Osman C, Muammer B, Murat O, Tamer A and
Fatih A: Osteoclast-type giant cell carcinoma of the urinary
bladder: An unusual and aggressive variant of urothelial carcinoma.
Urol Case Rep. 23:50–51. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Karasavvidou F, Mitrakas L, Strataki M,
Anastasiou D, Koukoulis G and Tzortzis V: Poorly differentiated
muscle-invasive giant cell tumor of the bladder leads to
unfavorable clinical outcome. J Surg Case Rep.
2022(rjac046)2022.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Satturwar S, Parwani AV, Thomas R,
Bastacky S, Dhir R and Quiroga-Garza GM: The osteoclast-type giant
cell rich carcinoma of urinary bladder: A case series. Pathol Res
Pract. 239(154164)2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
WHO Classification of Tumours Editorial
Board: Urinary and male genital tumours 5th edition. International
Agency for Research on Cancer, Lyon, France, 2022.
|
|
13
|
Mizutani K, Hirade K, Sugiyama S, Kato Y,
Nishihara H and Ishihara S: Genomic landscape of treatment-naive
urological cancers using next-generation sequencing-based panel
test in the Japanese population. Int J Urol. 29:909–911.
2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Shimozaki K, Hayashi H, Tanishima S, Horie
S, Chida A, Tsugaru K, Togasaki K, Kawasaki K, Aimono E, Hirata K,
et al: Concordance analysis of microsatellite instability status
between polymerase chain reaction based testing and next generation
sequencing for solid tumors. Sci Rep. 11(20003)2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Warrick JI: Clinical significance of
histologic variants of bladder cancer. J Natl Compr Canc Netw.
15:1268–1274. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Monn MF, Kaimakliotis HZ, Pedrosa JA, Cary
KC, Bihrle R, Cheng L and Koch MO: Contemporary bladder cancer:
Variant histology may be a significant driver of disease. Urol
Oncol. 33:18.e15–18.e20. 2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Mori K, Abufaraj M, Mostafaei H, Quhal F,
Karakiewicz PI, Briganti A, Kimura S, Egawa S and Shariat SF: A
systematic review and meta-analysis of variant histology in
urothelial carcinoma of the bladder treated with radical
cystectomy. J Urol. 204:1129–1140. 2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Eble JN, Argani P, Grignon DJ and Cheng L:
American Registry of Pathology: Tumors of the kidney, bladder, and
related urinary structures. American Registry of Pathology
Arlington, Virginia, Arlington, Virginia, 2022.
|
|
19
|
Allin KH, Bojesen SE and Nordestgaard BG:
Baseline C-reactive protein is associated with incident cancer and
survival in patients with cancer. J Clin Oncol. 27:2217–2224.
2009.PubMed/NCBI View Article : Google Scholar
|
|
20
|
O'Brian D, Prunty M, Hill A and Shoag J:
The role of C-reactive protein in kidney, bladder, and prostate
cancers. Front Immunol. 12(721989)2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Mizutani K, Sud S and Pienta KJ: Prostate
cancer promotes CD11b positive cells to differentiate into
osteoclasts. J Cell Biochem. 106:563–569. 2009.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Nassar AH, Umeton R, Kim J, Lundgren K,
Harshman L, Van Allen EM, Preston M, Dong F, Bellmunt J, Mouw KW,
et al: Mutational analysis of 472 urothelial carcinoma across
grades and anatomic sites. Clin Cancer Res. 25:2458–2470.
2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Robertson AG, Kim J, Al-Ahmadie H,
Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA,
Akbani R, et al: Comprehensive molecular characterization of
muscle-invasive bladder cancer. Cell. 171:540–556 e525.
2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Pietzak EJ, Bagrodia A, Cha EK, Drill EN,
Iyer G, Isharwal S, Ostrovnaya I, Baez P, Li Q, Berger MF, et al:
Next-generation sequencing of nonmuscle invasive bladder cancer
reveals potential biomarkers and rational therapeutic targets. Eur
Urol. 72:952–959. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Springer SU, Chen CH, Pena MDC, Li L,
Douville C, Wang Y, Cohen JD, Taheri D, Silliman N, Schaefer J, et
al: Non-invasive detection of urothelial cancer through the
analysis of driver gene mutations and aneuploidy. Elife.
7(e32143)2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Shuai H, Duan X, Zhou JJ, Liu Y and Wu T:
Effect of the TERT mutation on the prognosis of patients with
urothelial carcinoma: A systematic review and meta-analysis. BMC
Urol. 23(177)2023.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Yang G, Yin J, Ou K, Du Q, Ren W, Jin Y,
Peng L and Yang L: Undifferentiated carcinoma with osteoclast-like
giant cells of the pancreas harboring KRAS and BRCA mutations: Case
report and whole exome sequencing analysis. BMC Gastroenterol.
20(202)2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Luchini C, Pea A, Lionheart G, Mafficini
A, Nottegar A, Veronese N, Chianchiano P, Brosens LA, Noë M,
Offerhaus GJA, et al: Pancreatic undifferentiated carcinoma with
osteoclast-like giant cells is genetically similar to, but
clinically distinct from, conventional ductal adenocarcinoma. J
Pathol. 243:148–154. 2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Yamamoto S and Sakai Y: A case of
undifferentiated carcinoma with osteoclast-like giant cells of the
pancreas derived from an intraductal papillary mucinous neoplasm.
Clin J Gastroenterol. 14:1263–1268. 2021.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Chen Z, Ji J, Yung E, Martin SE and Walia
S: Uterine leiomyosarcoma with osteoclast-like giant cells: Report
of 2 cases and review of literature. Int J Gynecol Pathol.
43:182–189. 2023.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Besaw RJ, Terra AR, Malvar GL, Chapman TR,
Hertan LM and Schlechter BL: Durable response to PD-1 blockade in a
patient with metastatic pancreatic undifferentiated carcinoma with
osteoclast-like giant cells. J Natl Compr Canc Netw. 19:247–252.
2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Flaig TW, Spiess PE, Abern M, Agarwal N,
Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander
T, et al: NCCN Guidelines® insights: Bladder cancer,
version 2.2022. J Natl Compr Canc Netw. 20:866–878. 2022.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Cathomas R, Lorch A, Bruins HM, Comperat
EM, Cowan NC, Efstathiou JA, Fietkau R, Gakis G, Hernandez V,
Espinos EL, et al: The 2021 updated European association of urology
guidelines on metastatic urothelial carcinoma. Eur Urol. 81:95–103.
2022.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Grossman HB, Natale RB, Tangen CM,
Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF,
Wood DP Jr, Raghavan D, et al: Neoadjuvant chemotherapy plus
cystectomy compared with cystectomy alone for locally advanced
bladder cancer. N Engl J Med. 349:859–866. 2003.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Plimack ER, Dunbrack RL, Brennan TA,
Andrake MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi
E, Palma N, et al: Defects in DNA repair genes predict response to
neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder
cancer. Eur Urol. 68:959–967. 2015.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Teo MY, Bambury RM, Zabor EC, Jordan E,
Al-Ahmadie H, Boyd ME, Bouvier N, Mullane SA, Cha EK, Roper N, et
al: DNA damage response and repair gene alterations are associated
with improved survival in patients with platinum-treated advanced
urothelial carcinoma. Clin Cancer Res. 23:3610–3618.
2017.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Lee SH, Cheon J, Lee S, Kang B, Kim C,
Shim HS, Park YN, Jung S, Choi SH, Choi HJ, et al: ARID1A mutation
from targeted next-generation sequencing predicts primary
resistance to gemcitabine and cisplatin chemotherapy in advanced
biliary tract cancer. Cancer Res Treat. 55:1291–1302.
2023.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Bagrodia A, Lee BH, Lee W, Cha EK,
Sfakianos JP, Iyer G, Pietzak EJ, Gao SP, Zabor EC, Ostrovnaya I,
et al: Genetic determinants of cisplatin resistance in patients
with advanced germ cell tumors. J Clin Oncol. 34:4000–4007.
2016.PubMed/NCBI View Article : Google Scholar
|
